SCHEMBL1462801

SCHEMBL1462801

CC1(C(=O)O)CCNC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20294369 1.00
SCHEMBL20293460 1.00
Hydrochloric Acid SCHEMBL22655436 0.98 FFAR3 (0.50)
Hydrochloric Acid SCHEMBL1463754 0.98 FFAR3 (0.50)
SCHEMBL1131765 0.86 FFAR3 (0.48)
SCHEMBL20502872 0.86 FFAR3 (0.48)
SCHEMBL15415368 0.86 FFAR3 (0.48)
SCHEMBL1292520 0.85 FFAR3 (0.65)
Hydrochloric Acid SCHEMBL6995127 0.85 FFAR3 (0.46)
Hydrochloric Acid SCHEMBL31412240 0.85 FFAR3 (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114846013-B Novel aminoaryl derivatives useful as diacylglycerol acyltransferase 2 inhibitors and uses thereof 株式会社LG化学 2024-12-20 CN claimed
CN-112135824-B Heterocyclic compounds as immunomodulators 因赛特公司 2024-11-05 CN claimed
CN-110582493-B Benzoxazole derivatives as immunomodulators 因赛特公司 2024-03-08 CN claimed
EP-4234030-B1 PD-1/PD-L1 INHIBITORS GILEAD SCIENCES INC (US) 2026-04-08 EP disclosed
US-20260069605-A1 KRAS INHIBITORS INCYTE CORP (US) 2026-03-12 US disclosed
EP-4013749-B1 ALKYNYL QUINAZOLINE COMPOUNDS BLACK DIAMOND THERAPEUTICS INC (US) 2026-03-11 EP disclosed
US-20260049063-A1 ALKYNYL QUINAZOLINE COMPOUNDS BLACK DIAMOND THERAPEUTICS INC (US) 2026-02-19 US disclosed
US-20260034126-A1 KRAS INHIBITORS INCYTE CORP (US) 2026-02-05 US disclosed
EP-4045037-B1 HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES CHEMOCENTRYX INC (US) 2026-01-28 EP disclosed
US-20250368641-A1 QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS INCYTE CORP (US) 2025-12-04 US disclosed
US-20250346598-A1 HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES CHEMOCENTRYX, INC. (US) 2025-11-13 US disclosed
WO-2011095452-A1 ARYL BENZYLAMINE COMPOUNDS NOVARTIS AG (CH) 2011-08-11 WO disclosed
US-20110190258-A1 ARYL BENZYLAMINE COMPOUNDS NOVARTIS AG (CH) 2011-08-04 US disclosed
WO-2011033053-A1 MACROCYCLIC INHIBITORS OF JAK F. HOFFMANN-LA ROCHE AG (CH) 2011-03-24 WO disclosed
WO-2011033053-A1 MACROCYCLIC INHIBITORS OF JAK F. HOFFMANN-LA ROCHE AG (CH) 2011-03-24 WO disclosed
US-20110071179-A1 MACROCYCLIC INHIBITORS OF JAK JAHANGIR ALAM 2011-03-24 US disclosed
US-20110071179-A1 MACROCYCLIC INHIBITORS OF JAK JAHANGIR ALAM 2011-03-24 US disclosed
US-20110071179-A1 MACROCYCLIC INHIBITORS OF JAK JAHANGIR ALAM 2011-03-24 US disclosed
WO-2010138589-A1 BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE GENENTECH, INC. (US) 2010-12-02 WO disclosed
US-20100190764-A1 Novel compounds GLAXO GROUP LIMITED 2010-07-29 US disclosed